

# Global Edaravone API Market Growth 2023-2029

<https://marketpublishers.com/r/GCC6B79A215EEN.html>

Date: March 2023

Pages: 93

Price: US\$ 3,660.00 (Single User License)

ID: GCC6B79A215EEN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral sclerosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion injury, and myocardial infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properties, it is therapeutically advantageous in crossing the blood-brain barrier to mediate neurotropic and neuroprotective effects. Oral formulation of edaravone is currently under development.

LPI (LP Information)' newest research report, the "Edaravone API Industry Forecast" looks at past sales and reviews total world Edaravone API sales in 2022, providing a comprehensive analysis by region and market sector of projected Edaravone API sales for 2023 through 2029. With Edaravone API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Edaravone API industry.

This Insight Report provides a comprehensive analysis of the global Edaravone API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Edaravone API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Edaravone API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Edaravone API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Edaravone API.

The global Edaravone API market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Edaravone API is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Edaravone API is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Edaravone API is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Edaravone API players cover Dr. Reddy's Laboratories Ltd., ChemWerth Inc, Medichem S.A, Solara Active Pharma Sciences, Neuland Laboratories and Jiangsu Haici Bio-Pharmaceutical Co., Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Edaravone API market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Purity?98%

Purity

## Contents

### **1 SCOPE OF THE REPORT**

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### **2 EXECUTIVE SUMMARY**

- 2.1 World Market Overview
  - 2.1.1 Global Edaravone API Annual Sales 2018-2029
  - 2.1.2 World Current & Future Analysis for Edaravone API by Geographic Region, 2018, 2022 & 2029
  - 2.1.3 World Current & Future Analysis for Edaravone API by Country/Region, 2018, 2022 & 2029
- 2.2 Edaravone API Segment by Type
  - 2.2.1 Purity?98%
  - 2.2.2 Purity

## List Of Tables

### LIST OF TABLES

Table 1. Edaravone API Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Edaravone API Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Purity?98%

Table 4. Major Players of Purity

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Edaravone API
- Figure 2. Edaravone API Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Edaravone API Sales Growth Rate 2018-2029 (Ton)
- Figure 7. Global Edaravone API Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Edaravone API Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Purity?98%
- Figure 10. Product Picture of Purity

## I would like to order

Product name: Global Edaravone API Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GCC6B79A215EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCC6B79A215EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970